EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Lipid Nanoparticle‐Based Disease Treatment

Yujie Zhou, Qiqi Ge, Xin Wang, Yuhui Wang, Qianqian Sun, Jianhao Wang, Tie Yang, Cheng Wang iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400938 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2025. Verfasst von Yujie Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China (Jianhao Wang), (Cheng Wang. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Neoplasms, Communicable Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 180 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles (LNPs) have emerged as a transformative platform for the targeted delivery of therapeutic agents, revolutionizing treatment paradigms across a spectrum of diseases. Since the inception of liposomes in the 1960s, lipid‐based nanotechnology has evolved to address limitations such as poor bioavailability, off‐target effects, and instability, thereby enhancing the efficacy and safety of drug administration. This review highlights the latest advancements in LNPs technology, focusing on their application in cancer therapy, gene therapy, infectious disease management, glaucoma, and other clinical areas. Recent studies underscore the potential of LNPs to deliver messenger RNA (mRNA) and small interfering RNA (siRNA) for precise genetic intervention, exemplified by breakthroughs in RNA interference and CRISPR‐Cas9 genome editing. Additionally, LNPs have been successfully employed to ameliorate conditions, demonstrating their versatility in addressing both acute and chronic disorders. However, challenges persist concerning large‐scale manufacturing, long‐term stability, and comprehensive safety evaluations. Future research must focus on optimizing formulations, exploring synergistic combinations with existing therapies, and expanding the scope of treatable diseases. The integration of LNPs into personalized medicine and the exploration of applications in other diseases represent promising avenues for further investigation. LNPs are poised to play an increasingly central role in the development of next‐generation therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsNeoplasmsCommunicable DiseasesHumansRNA, Small InterferingGenetic TherapyAnimalsGlaucomaLiposomes

Stichwörter der Autor:innen

Disease treatmentLNPsLiposomeNanostructured lipid carriersSolid lipid nanoparticles

Substanzen

LipidsRNA, Small InterferingLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China (Jianhao Wang), (Cheng Wang.
  • Chia Tai Tianqing Pharmaceutical Group Co., LTD, Nanjing, 211100, Jiangsu, China.

ORCID-Profile: Cheng Wang

Zitieren

APA

Zhou, Y., Ge, Q., Wang, X., Wang, Y., Sun, Q., Wang, J., Yang, T., & Wang, C. (2025). Advances in Lipid Nanoparticle‐Based Disease Treatment. ChemMedChem. https://doi.org/10.1002/cmdc.202400938

Vancouver

Zhou Y, Ge Q, Wang X, Wang Y, Sun Q, Wang J, et al. Advances in Lipid Nanoparticle‐Based Disease Treatment. ChemMedChem. 2025. doi:10.1002/cmdc.202400938

BibTeX
@article{Zhou2025,
  author = {Zhou, Yujie and Ge, Qiqi and Wang, Xin and Wang, Yuhui and Sun, Qianqian and Wang, Jianhao and Yang, Tie and Wang, Cheng},
  title = {Advances in Lipid Nanoparticle‐Based Disease Treatment},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400938}
}
Kostenlos starten →